The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

TFDP1  -  transcription factor Dp-1

Homo sapiens

Synonyms: DP1, DRTF1, DRTF1-polypeptide 1, Dp-1, E2F dimerization partner 1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of TFDP1


High impact information on TFDP1


Chemical compound and disease context of TFDP1

  • To investigate the relationship between E2F-1 and drug sensitivity in detail, we established human osteosarcoma U-20S-TA cells expressing full-length E2F-1/ DP-1 under the control of a tetracycline-responsive promoter, designated UE1DP-1 cells [9].

Biological context of TFDP1


Anatomical context of TFDP1


Associations of TFDP1 with chemical compounds

  • When the hydroxymethyl glutaryl coenzyme A reductase promoter was used to express DP-1, overexpression occurred in a variety of tissues and did not confer phenotypic changes [17].
  • Celecoxib resulted in a significant reduction of retinoblastoma phosphorylation and DP1/E2F1 complex in both cells [18].
  • The second photoreaction process is photocyclization of cis-BSF, which occurs to give DP1 decaying with the half lifetime (tau1/2) of 2.8-4.0 micros to produce another DHP-type intermediate (DP2) with an absorption peak at 400 nm in the absence of O2, through [1,9]-hydrogen shift [19].
  • In addition, PGD2 has both pro- and anti-inflammatory effects via the adenylyl cyclase-coupled DP1 receptor [20].

Physical interactions of TFDP1

  • To assess transactivating activity of E2F1/DP-1, we also analyzed expression of ten putative transcriptional targets of this complex in HCCs [1].
  • We show that ARF directly binds to DP1 [21].

Regulatory relationships of TFDP1

  • Moreover, ARF regulates the association of DP1 with its target gene, as evidenced by a chromatin immunoprecipitation assay with the dhfr promoter [21].
  • We show that E2F5 can promote the formation of morphologically transformed foci in primary baby rat kidney cells (BRK) when it is overexpressed in the presence of its heterodimeric partner DP1 and activated RAS [22].
  • Inhibition of E2F-4/DP-1-stimulated transcription by p202 [23].
  • The cell cycle-regulating transcription factors E2F1/DP1 activate genes whose products are required for S phase progression [24].
  • SOCS-3 inhibited E2F/DP-1 transcriptional activity under the cyclin-E promoter and actually inhibited cell cycle progression and cell growth under E2F/DP-1 control [25].

Other interactions of TFDP1

  • A new component of the transcription factor DRTF1/E2F [26].
  • Although present at very different levels, DP-1 and DP-2 are evenly distributed among each of these complexes [27].
  • In conclusion, our findings suggest that TFDP1, CUL4A, and CDC16 are probable targets of an amplification mechanism and therefore may be involved, together or separately, in development and/or progression of some HCCs [14].
  • E2F-5, only in conjunction with DP1, promoted cell cycle progression [28].
  • By analyzing a series of ARF mutants, we demonstrate a strong correlation between ARF's ability to regulate DP1 and its ability to cause cell cycle arrest [21].

Analytical, diagnostic and therapeutic context of TFDP1


  1. Association of over-expressed TFDP1 with progression of hepatocellular carcinomas. Yasui, K., Okamoto, H., Arii, S., Inazawa, J. J. Hum. Genet. (2003) [Pubmed]
  2. Deregulated E2F transcriptional activity in autonomously growing melanoma cells. Halaban, R., Cheng, E., Smicun, Y., Germino, J. J. Exp. Med. (2000) [Pubmed]
  3. Genomic cloning and chromosomal assignment of the E2F dimerization partner TFDP gene family. Zhang, Y., Venkatraj, V.S., Fischer, S.G., Warburton, D., Chellappan, S.P. Genomics (1997) [Pubmed]
  4. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Rubin, S.M., Gall, A.L., Zheng, N., Pavletich, N.P. Cell (2005) [Pubmed]
  5. Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Bandara, L.R., La Thangue, N.B. Nature (1991) [Pubmed]
  6. DP and E2F proteins: coordinating transcription with cell cycle progression. Lam, E.W., La Thangue, N.B. Curr. Opin. Cell Biol. (1994) [Pubmed]
  7. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Beijersbergen, R.L., Kerkhoven, R.M., Zhu, L., Carlée, L., Voorhoeve, P.M., Bernards, R. Genes Dev. (1994) [Pubmed]
  8. HCCR-1-interacting molecule "deleted in polyposis 1" plays a tumor-suppressor role in colon carcinogenesis. Shin, S.M., Chung, Y.J., Oh, S.T., Jeon, H.M., Hwang, L.J., Namkoong, H., Kim, H.K., Cho, G.W., Hur, S.Y., Kim, T.E., Lee, Y.S., Park, Y.G., Ko, J., Kim, J.W. Gastroenterology (2006) [Pubmed]
  9. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Hofland, K., Petersen, B.O., Falck, J., Helin, K., Jensen, P.B., Sehested, M. Clin. Cancer Res. (2000) [Pubmed]
  10. Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F. Bandara, L.R., Buck, V.M., Zamanian, M., Johnston, L.H., La Thangue, N.B. EMBO J. (1993) [Pubmed]
  11. Functional interaction between DP-1 and p53. Sørensen, T.S., Girling, R., Lee, C.W., Gannon, J., Bandara, L.R., La Thangue, N.B. Mol. Cell. Biol. (1996) [Pubmed]
  12. The role of the transcription factor DP in apoptosis. Hitchens, M.R., Robbins, P.D. Apoptosis (2003) [Pubmed]
  13. Association with E2F-1 governs intracellular trafficking and polyubiquitination of DP-1. Magae, J., Illenye, S., Chang, Y.C., Mitsui, Y., Heintz, N.H. Oncogene (1999) [Pubmed]
  14. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Yasui, K., Arii, S., Zhao, C., Imoto, I., Ueda, M., Nagai, H., Emi, M., Inazawa, J. Hepatology (2002) [Pubmed]
  15. Immunohistochemical expression of the transcription factor DP-1 and its heterodimeric partner E2F-1 in non-Hodgkin lymphoma. Chan, J.A., Olvera, M., Lai, R., Naing, W., Rezk, S.A., Brynes, R.K. Appl. Immunohistochem. Mol. Morphol. (2002) [Pubmed]
  16. Cloning, chromosomal location, and characterization of mouse E2F1. Li, Y., Slansky, J.E., Myers, D.J., Drinkwater, N.R., Kaelin, W.G., Farnham, P.J. Mol. Cell. Biol. (1994) [Pubmed]
  17. E2F-1-induced p53-independent apoptosis in transgenic mice. Holmberg, C., Helin, K., Sehested, M., Karlström, O. Oncogene (1998) [Pubmed]
  18. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Cui, W., Yu, C.H., Hu, K.Q. Clin. Cancer Res. (2005) [Pubmed]
  19. Dihydrophenanthrene-type intermediates during photoreaction of trans-4'-benzyl-5-styrylfuran. Samori, S., Hara, M., Ho, T.I., Tojo, S., Kawai, K., Endo, M., Fujitsuka, M., Majima, T. J. Org. Chem. (2005) [Pubmed]
  20. 15R-methyl-prostaglandin D2 is a potent and selective CRTH2/DP2 receptor agonist in human eosinophils. Monneret, G., Cossette, C., Gravel, S., Rokach, J., Powell, W.S. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  21. ARF directly binds DP1: interaction with DP1 coincides with the G1 arrest function of ARF. Datta, A., Sen, J., Hagen, J., Korgaonkar, C.K., Caffrey, M., Quelle, D.E., Hughes, D.E., Ackerson, T.J., Costa, R.H., Raychaudhuri, P. Mol. Cell. Biol. (2005) [Pubmed]
  22. Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors. Polanowska, J., Le Cam, L., Orsetti, B., Vallés, H., Fabbrizio, E., Fajas, L., Taviaux, S., Theillet, C., Sardet, C. Genes Chromosomes Cancer (2000) [Pubmed]
  23. Inhibition of E2F-4/DP-1-stimulated transcription by p202. Choubey, D., Gutterman, J.U. Oncogene (1997) [Pubmed]
  24. The CBP co-activator stimulates E2F1/DP1 activity. Trouche, D., Cook, A., Kouzarides, T. Nucleic Acids Res. (1996) [Pubmed]
  25. SOCS-3 inhibits E2F/DP-1 transcriptional activity and cell cycle progression via interaction with DP-1. Masuhiro, Y., Kayama, K., Fukushima, A., Baba, K., Soutsu, M., Kamiya, Y., Gotoh, M., Yamaguchi, N., Hanazawa, S. J. Biol. Chem. (2008) [Pubmed]
  26. A new component of the transcription factor DRTF1/E2F. Girling, R., Partridge, J.F., Bandara, L.R., Burden, N., Totty, N.F., Hsuan, J.J., La Thangue, N.B. Nature (1993) [Pubmed]
  27. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Moberg, K., Starz, M.A., Lees, J.A. Mol. Cell. Biol. (1996) [Pubmed]
  28. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells. Dirks, P.B., Rutka, J.T., Hubbard, S.L., Mondal, S., Hamel, P.A. Oncogene (1998) [Pubmed]
  29. Identification and characterization of novel isoforms of human DP-1: DP-1{alpha} regulates the transcriptional activity of E2F1 as well as cell cycle progression in a dominant-negative manner. Ishida, H., Masuhiro, Y., Fukushima, A., Argueta, J.G., Yamaguchi, N., Shiota, S., Hanazawa, S. J. Biol. Chem. (2005) [Pubmed]
  30. Expression of dominant-negative mutant DP-1 blocks cell cycle progression in G1. Wu, C.L., Classon, M., Dyson, N., Harlow, E. Mol. Cell. Biol. (1996) [Pubmed]
WikiGenes - Universities